

PRESS RELEASE



Cenetron Diagnostics Announces the Acquisition of RCRC IRB

AUSTIN, Texas (September 2, 2008) – Cenetron Diagnostics, Ltd today announced that it has acquired RCRC IRB, an independent review board that has served the pharmaceutical and CRO industries since 1985.

Based in Austin, Texas, RCRC IRB maintains two permanent review boards of professionals from the medical, legal and social service sectors in addition to members from the community at large. Priscilla Short will oversee the ethical review board as executive director of RCRC, drawing upon her strong experience and leadership in human subject protection as an IRB specialist. Cenetron will retain all board members and a majority of the current RCRC IRB staff.

Cenetron will operate the business as *RCRC Independent Review Board* www.rcrc-irb.com and has relocated its administrative offices within Austin.

“We are very excited about this acquisition,” said Dwight DuBois, M.D., president of Cenetron. “RCRC IRB has built a solid reputation with a proven 20-year history in the industry. Its permanent review boards and professional staff have strong expertise and a depth and breadth of experience that are very difficult to match. Cenetron will provide *RCRC Independent Review Board* with state-of-the-art data management and information technologies to assist it in fulfilling its obligations to human subjects.”

Cenetron acquired RCRC IRB from PPD, Inc. The terms of the acquisition were not disclosed.

Cenetron Diagnostics is a premier provider of molecular laboratory services, providing support for anti-viral and oncology drug development programs, and pharmacogenomics. Founded in 1995, Cenetron has supported pivotal global trials in North and South America, Europe, Africa and the Pacific Rim. Cenetron’s client list includes leading pharmaceutical clients in the United States and Europe. For further information visit www.cenetron.com

MEDIA CONTACT:

Jason Guin

jguin@cenetron.com

www.rcrc-irb.com